La cadena de opciones muestra datos clave de las opciones de acciones de Abeona Therapeutics a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Abeona Therapeutics..

Abeona Therapeutics (NASDAQ:ABEO) Bolsa, Cadena de Opciones

Abeona Therapeutics

Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.

Abeona Therapeutics Inc

HC Wainwright &amp; Co. analyst Mitchell Kapoor reiterates Abeona Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABEO#NASDAQ">ABEO</a>) with a Buy and maintains $15 price target.

News

Price Target

Reiteration

Analyst Ratings

ABEO

HC Wainwright & Co. Reiterates Buy on Abeona Therapeutics, Maintains $15 Price Target

Earnings

Abeona Therapeutics 2024 EPS $(1.55) Up From $(2.53) YoY

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Canaccord Genuity analyst John Newman initiated coverage on Marker Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRKR#NASDAQ">MRKR</a>) with a Buy rating and announced a price target of $8. Marker Therapeutics shares closed at $1.38 on Tuesday. <a href="https://www.benzinga.com/quote/mrkr/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jefferies analyst Roger Song initiated coverage on Krystal Biotech, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRYS#NASDAQ">KRYS</a>) with a Buy rating and announced a price target of $245. Krystal Biotech shares closed at $175.22 on Tuesday. <a href="https://www.benzinga.com/quote/krys/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Barclays analyst Thomas O&#8217;Malley initiated coverage on Sandisk Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDK#NASDAQ">SNDK</a>) with an Equal-Weight rating and announced a price target of $50. SanDisk shares closed at $48.69 on Tuesday. <a href="https://www.benzinga.com/quote/sndk/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Mizuho analyst Maheep Mandloi initiated coverage on Fluence Energy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLNC#NASDAQ">FLNC</a>) with an Outperform rating and announced a price target of $8. Fluence Energy shares closed at $5.21 on Tuesday. <a href="https://www.benzinga.com/quote/flnc/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Oppenheimer analyst Francois Brisebois initiated coverage on Abeona Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABEO#NASDAQ">ABEO</a>) with an Outperform rating and announced a price target of $16. Abeona Therapeutics shares closed at $5.07 on Tuesday. <a href="https://www.benzinga.com/quote/abeo/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/03/44083539/wall-streets-most-accurate-analysts-give-their-take-on-3-defensive-stocks-delivering-high-dividend-yields-3">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Defensive Stocks Delivering High-Dividend Yields</a></li>
</ul>

Initiation

Markets

Trading Ideas

FLNC

KRYS

MRKR

SNDK

This Krystal Biotech Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday

Oppenheimer analyst Francois Brisebois initiates coverage on Abeona Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABEO#NASDAQ">ABEO</a>) with a Outperform rating and announces Price Target of $16.

Oppenheimer Initiates Coverage On Abeona Therapeutics with Outperform Rating, Announces Price Target of $16

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates Abeona Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABEO#NASDAQ">ABEO</a>) with a Buy and maintains $15 price target.

Abeona Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABEO#NASDAQ">ABEO</a>) reported quarterly losses of $(0.63) per share which missed the analyst consensus estimate of $(0.40) by 57.5 percent. This is a 31.25 percent decrease over losses of $(0.48) per share from the same period last year.

Earnings Misses

Abeona Therapeutics Q3 2024 GAAP EPS $(0.63) Misses $(0.40) Estimate

Abeona Therapeutics Announces FDA Acceptance Of BLA Resubmission For Pz-cel In Recessive Dystrophic Epidermolysis Bullosa

Cantor Fitzgerald analyst Kristen Kluska reiterates Abeona Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABEO#NASDAQ">ABEO</a>) with a Overweight and maintains $18 price target.

Cantor Fitzgerald Reiterates Overweight on Abeona Therapeutics, Maintains $18 Price Target

Biotech

Health Care

General

Abeona Therapeutics Has Resubmitted Its Biologics License Application To The FDA For Prademagene Zamikeracel (Pz-cel), Its Investigational Autologous Cell-based Gene Therapy For Recessive Dystrophic Epidermolysis Bullosa

If pz-cel receives U.S. marketing approval, this code will allow for efficient and accurate documentation, billing, and analysis of inpatient hospital procedures using pz-cel. The code will go into effect on October 1, 2024.

The Centers For Medicare And Medicaid Services Has Granted A Product-specific Procedure Code Icd-10-PCS For Abeona Therapeutics' Prademagene Zamikeracel (Pz-cel), Investigational Autologous Cell-based Gene Therapy Currently In Development For Recessive Dystrophic Epidermolysis Bullosa

WIIM

Abeona Therapeutics shares are trading higher after the company reported better-than-expected Q2 EPS results.

Earnings Beats

Abeona Therapeutics Q2 EPS $(0.26) Beats $(0.36) Estimate, Cash Balance $123M

Abeona Therapeutics Concludes Type A Meeting With FDA To Align On Upcoming Pz-cel BLA Resubmission, Continues To Expect To Resubmit BLA In Second Half Of 2024

Under the terms of the agreement, Beacon will have the right to evaluate, for a 12-month period, the AAV204 capsid for potential use in certain ophthalmology indications, with an option to take a worldwide, non-exclusive license to use AAV204 in connection with up to five gene or disease targets. Beacon will also have the right to use AAV204 for up to four additional nominated gene or disease targets subject to certain conditions. Under the agreement, Abeona will receive an upfront payment upon Beacon&#39;s exercise of its option to license AAV204, with additional payments upon the achievement of certain development, regulatory, and sales milestones, along with tiered royalties on worldwide net sales for licensed products incorporating AAV204. Beacon will be responsible for the development and commercialization of all licensed products. The targets for which Beacon would receive rights under its non-exclusive license agreement are distinct from those currently in development at Abeona.

Contracts

Abeona Therapeutics And Beacon Therapeutics Announced An Agreement By Which Beacon Will Evaluate Abeona's Patented AAV204 Capsid For The Development And Commercialization Of Potential Gene Therapies For Select Ophthalmology Indications

HC Wainwright &amp; Co. analyst Raghuram Selvaraju initiates coverage on Abeona Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABEO#NASDAQ">ABEO</a>) with a Buy rating and announces Price Target of $15.

HC Wainwright & Co. Initiates Coverage On Abeona Therapeutics with Buy Rating, Announces Price Target of $15

Press Releases

Abeona Therapeutics® Announces Participation in November Investor Conferences

Abeona Therapeutics® Announces FDA Acceptance of BLA Resubmission of Pz-cel for the Treatment of Recessive Dystrophic Epidermolysis Bullosa

Abeona Therapeutics® Reports Third Quarter 2024 Financial Results and Recent Corporate Updates

Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Abeona Therapeutics® to Present at the Leerink Partners Global Healthcare Conference

Abeona Therapeutics® Reports Full Year 2024 Financial Results, Provides Pz-cel Regulatory Update and Commercial Launch Plans

Comments

Abeona Therapeutics

Abeona Therapeutics (ABEO) Opciones

Abeona Therapeutics (NASDAQ:ABEO) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL